| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hyperemesis Gravidarum | D006939 | 2 associated lipids |
| Empyema, Pleural | D016724 | 2 associated lipids |
| Mastoiditis | D008417 | 2 associated lipids |
| Pityriasis Rosea | D017515 | 3 associated lipids |
| Duodenogastric Reflux | D004383 | 2 associated lipids |
| Tuberculosis, Multidrug-Resistant | D018088 | 6 associated lipids |
| Scrub Typhus | D012612 | 3 associated lipids |
| Tuberculosis, Avian | D014379 | 2 associated lipids |
| Typhoid Fever | D014435 | 2 associated lipids |
| Central Nervous System Protozoal Infections | D020808 | 3 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Arain TM et al. | Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. | 1996 | Antimicrob. Agents Chemother. | pmid:8726034 |
| Hirschl AM et al. | In vitro activities of linezolid alone and in combination with amoxicillin, clarithromycin, and metronidazole against Helicobacter pylori. | 2000 | Antimicrob. Agents Chemother. | pmid:10858365 |
| Roblin PM et al. | In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. | 2010 | Antimicrob. Agents Chemother. | pmid:20038627 |
| Nagashima A et al. | Clarithromycin Suppresses Chloride Channel Accessory 1 and Inhibits Interleukin-13-Induced Goblet Cell Hyperplasia in Human Bronchial Epithelial Cells. | 2016 | Antimicrob. Agents Chemother. | pmid:27550358 |
| Perronne C et al. | Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. | 1990 | Antimicrob. Agents Chemother. | pmid:2171421 |
| Jung R et al. | Postantibiotic effects and bactericidal activities of clarithromycin-14-hydroxy-clarithromycin, versus those of amoxicillin-clavulanate, against anaerobes. | 2000 | Antimicrob. Agents Chemother. | pmid:10681358 |
| Sassa K et al. | Therapeutic effect of clarithromycin on a transplanted tumor in rats. | 1999 | Antimicrob. Agents Chemother. | pmid:9869567 |
| Loreto ES et al. | New insights into the in vitro susceptibility of Pythium insidiosum. | 2014 | Antimicrob. Agents Chemother. | pmid:25223997 |
| Clark C et al. | In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin. | 2002 | Antimicrob. Agents Chemother. | pmid:12183253 |
| Hunt Gerardo S et al. | Comparison of Etest to broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. | 1996 | Antimicrob. Agents Chemother. | pmid:8891154 |
| Lemaire S et al. | Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. | 2009 | Antimicrob. Agents Chemother. | pmid:19564365 |
| Tamaoki J et al. | Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. | 1995 | Antimicrob. Agents Chemother. | pmid:7486901 |
| Fernandes PB et al. | In vitro and in vivo activities of clarithromycin against Mycobacterium avium. | 1989 | Antimicrob. Agents Chemother. | pmid:2530933 |
| Vance E et al. | Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. | 1995 | Antimicrob. Agents Chemother. | pmid:7574530 |
| Gikas A et al. | In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin. | 1998 | Antimicrob. Agents Chemother. | pmid:9756789 |
| Debets-Ossenkopp YJ et al. | Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori. | 1998 | Antimicrob. Agents Chemother. | pmid:9756790 |
| Diacon AH et al. | Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. | 2012 | Antimicrob. Agents Chemother. | pmid:22391540 |
| Pryjma M et al. | Antagonism between Front-Line Antibiotics Clarithromycin and Amikacin in the Treatment of Mycobacterium abscessus Infections Is Mediated by the Gene. | 2017 | Antimicrob. Agents Chemother. | pmid:28874379 |
| Bolhuis MS et al. | Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. | 2013 | Antimicrob. Agents Chemother. | pmid:23689722 |
| Conte JE et al. | Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. | 1995 | Antimicrob. Agents Chemother. | pmid:7726492 |
| Nagai K et al. | Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes. | 2001 | Antimicrob. Agents Chemother. | pmid:11600391 |
| Lazard T et al. | Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice. | 1993 | Antimicrob. Agents Chemother. | pmid:7684213 |
| Chu SY et al. | Absolute bioavailability of clarithromycin after oral administration in humans. | 1992 | Antimicrob. Agents Chemother. | pmid:1387301 |
| Yajko DM et al. | Comparison of the intracellular activities of clarithromycin and erythromycin against Mycobacterium avium complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals. | 1992 | Antimicrob. Agents Chemother. | pmid:1387302 |
| Zhanel GG et al. | Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. | 2008 | Antimicrob. Agents Chemother. | pmid:18285482 |
| Hardy RD et al. | Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia. | 2003 | Antimicrob. Agents Chemother. | pmid:12709330 |
| Tomioka H et al. | Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells. | 2002 | Antimicrob. Agents Chemother. | pmid:11796367 |
| Naik S and Ruck R | In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. | 1989 | Antimicrob. Agents Chemother. | pmid:2817858 |
| Klis S et al. | Compliance with antimicrobial therapy for buruli ulcer. | 2014 | Antimicrob. Agents Chemother. | pmid:25225342 |
| Bermudez LE et al. | Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. | 1998 | Antimicrob. Agents Chemother. | pmid:9449283 |
| Cheng KL et al. | Effect of grapefruit juice on clarithromycin pharmacokinetics. | 1998 | Antimicrob. Agents Chemother. | pmid:9559810 |
| Carr RA et al. | Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. | 1998 | Antimicrob. Agents Chemother. | pmid:9593146 |
| Sörberg M et al. | Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori. | 1998 | Antimicrob. Agents Chemother. | pmid:9593154 |
| Ji B et al. | Selection of resistant mutants of Mycobacterium avium in beige mice by clarithromycin monotherapy. | 1992 | Antimicrob. Agents Chemother. | pmid:1482155 |
| Rastogi N and Goh KS | Effect of pH on radiometric MICs of clarithromycin against 18 species of mycobacteria. | 1992 | Antimicrob. Agents Chemother. | pmid:1482156 |
| Rastogi N et al. | Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol. | 1992 | Antimicrob. Agents Chemother. | pmid:1482157 |
| Mougari F et al. | Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. | 2017 | Antimicrob. Agents Chemother. | pmid:27799212 |
| Ji B et al. | Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. | 1996 | Antimicrob. Agents Chemother. | pmid:8834886 |
| Kutlin A et al. | Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model. | 2002 | Antimicrob. Agents Chemother. | pmid:11796350 |
| Yamamoto T et al. | Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice. | 1996 | Antimicrob. Agents Chemother. | pmid:8834892 |
| Ji B et al. | How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice? | 1996 | Antimicrob. Agents Chemother. | pmid:8834894 |
| Alffenaar JW et al. | Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. | 2010 | Antimicrob. Agents Chemother. | pmid:20585115 |
| Kishii K et al. | In vitro activity of tebipenem, a new oral carbapenem antibiotic, against beta-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae. | 2010 | Antimicrob. Agents Chemother. | pmid:20585130 |
| Hoffman HL et al. | Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. | 2003 | Antimicrob. Agents Chemother. | pmid:12543686 |
| Fontana C et al. | New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates. | 2002 | Antimicrob. Agents Chemother. | pmid:12435674 |
| Noreddin AM et al. | Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations. | 2002 | Antimicrob. Agents Chemother. | pmid:12435719 |
| Cohen Y et al. | Use of normal C57BL/6 mice with established Mycobacterium avium infections as an alternative model for evaluation of antibiotic activity. | 1995 | Antimicrob. Agents Chemother. | pmid:7793882 |
| Furney SK et al. | Activities of rifabutin, clarithromycin, and ethambutol against two virulent strains of Mycobacterium avium in a mouse model. | 1995 | Antimicrob. Agents Chemother. | pmid:7793895 |
| Piccolomini R et al. | Bacteriostatic and bactericidal in vitro activities of clarithromycin and erythromycin against periodontopathic Actinobacillus actinomycetemcomitans. | 1998 | Antimicrob. Agents Chemother. | pmid:9797240 |
| Patel KB et al. | Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. | 1996 | Antimicrob. Agents Chemother. | pmid:8891147 |